Sign in

You're signed outSign in or to get full access.

Kevin Cullinane

Research Analyst at RBC Capital Markets

Kevin Cullinane is a Managing Director in the technology, media, and telecoms banking group at RBC Capital Markets in New York. He advises clients in the TMT sector, though specific company coverage details are not publicly detailed, and performance metrics such as success rates or returns are unavailable from available sources. Cullinane joined RBC in early 2025 after a brief stint at UBS from April 2024 to January 2025, following seven years at Barclays; his career includes an MBA from Yale School of Management (2012-2014). He holds FINRA registrations as a broker with RBC Capital Markets, LLC, with no reported violations.

Kevin Cullinane's questions to Kymera Therapeutics (KYMR) leadership

Question · Q4 2025

Kevin Cullinane asked about expectations for IRF5 degradation in PBMCs and skin in healthy volunteers, given that IRF5 is not highly activated in healthy individuals, and how this impacts the study's expectations.

Answer

CEO Nello Mainolfi confirmed that IRF5 degradation can be effectively measured in PBMCs using mass spectrometry. However, he noted that IRF5 expression is extremely low in healthy volunteer skin, making degradation difficult to assess in that tissue. He suggested that skin expression might be measurable in future patient studies, particularly in lupus patients with cutaneous manifestations.

Ask follow-up questions

Fintool

Fintool can predict Kymera Therapeutics logo KYMR's earnings beat/miss a week before the call